Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 14/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL390698 | 0.86 | GPR119 (0.44) | ARHRH3 | |
| SCHEMBL391762 | 0.85 | AR (0.36) | ARCNR2 | |
| SCHEMBL13404853 | 0.84 | AR (0.39) | ARCNR2HCRTR1HCRTR2 | |
| SCHEMBL391221 | 0.84 | AR (0.40) | ARCNR2 | |
| SCHEMBL387873 | 0.83 | GPR119 (0.47) | AR | |
| SCHEMBL390630 | 0.83 | AR (0.40) | AR | |
| SCHEMBL388927 | 0.82 | AR (0.39) | ARHCRTR1HCRTR2 | |
| SCHEMBL390985 | 0.82 | GPR119 (0.40) | AR | |
| SCHEMBL388822 | 0.79 | GPR119 (0.38) | CNR2TLR9TLR8TLR7 | |
| SCHEMBL12916006 | 0.79 | ALOX5AP (0.43) | ARTLR9TLR8TLR7HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2292620-A2 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prohylaxis and treatment of disorders related thereto | Arena Pharmaceuticals, Inc. (US) | 2011-03-09 | — | — | EP | claimed |
| EP-2287166-A2 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | Arena Pharmaceuticals, Inc. (US) | 2011-02-23 | — | — | EP | claimed |
| EP-2287165-A2 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | Arena Pharmaceuticals, Inc. (US) | 2011-02-23 | — | — | EP | claimed |
| US-20100093761-A1 | FUSED-ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | claimed |
| US-20070082874-A1 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICLAS, INC. (US) | 2007-04-12 | — | — | US | claimed |
| US-20070072844-A1 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2007-03-29 | — | — | US | claimed |
| US-20060142262-A1 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. | 2006-06-29 | — | — | US | claimed |
| US-20050059650-A1 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. | 2005-03-17 | — | — | US | claimed |
| US-8410119-B2 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410119-B2 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2013-04-02 | — | — | US | disclosed |
| EP-1758565-B2 | Method of identifying GLP-1 secretagogues | ARENA PHARM INC (US) | 2012-11-14 | — | — | EP | disclosed |
| US-8198232-B2 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | ARENA PHARMACEUTICALS, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-8101626-B2 | GPR119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto | ARENA PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8030270-B2 | Methods for identifying GLP-1 secretagogues | ARENA PHARMACEUTICALS, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-20070072844-A1 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2007-03-29 | — | — | US | disclosed |
| US-20070072844-A1 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2007-03-29 | — | — | US | disclosed |
| US-7132426-B2 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2006-11-07 | — | — | US | disclosed |
| US-20060154866-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | ARENA PHARMACEUTICALS, INC. | 2006-07-13 | — | — | US | disclosed |
| US-20060142262-A1 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. | 2006-06-29 | — | — | US | disclosed |
| US-20050059650-A1 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142262-A1 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | CYP7A1, CYP27A1, CYP4F3 | AR 1843/4885CNR2 1400/4885TLR9 4500/4885 |
| US-20070082874-A1 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | CYP7A1, CYP27A1, CYP4F3 | AR 1843/4885CNR2 1400/4885TLR9 4500/4885 |
| US-20100093761-A1 | FUSED-ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | CYP7A1, CYP27A1, CYP4F3 | AR 1843/4885CNR2 1400/4885TLR9 4500/4885 |
| US-20060154866-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | GLP1R, GPR119, GIPR | AR 1566/4885CNR2 564/4885TLR9 492/4885 |
| US-20050059650-A1 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | CYP7A1, CYP27A1, CYP4F3 | AR 1843/4885CNR2 1400/4885TLR9 4500/4885 |
| US-20070072844-A1 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | CYP7A1, CYP27A1, CYP4F3 | AR 1843/4885CNR2 1400/4885TLR9 4500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.